Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data.

Journal: PloS one
Published Date: Jun 2, 2021

Abstract

BACKGROUND: Pancreatic cancer (PC) represents a substantial public health burden. Pancreatic cancer patients have very low survival due to the difficulty of identifying cancers early when the tumour is localised to the site of origin and treatable. Recent progress has been made in identifying biomarkers for PC in the blood and urine, but these cannot be used for population-based screening as this would be prohibitively expensive and potentially harmful.

Authors

  • Ananya Malhotra
    Faculty of Epidemiology and Population Health, Department of Non-Communicable Disease Epidemiology, Inequalities in Cancer Outcomes Network, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • Bernard Rachet
    Faculty of Epidemiology and Population Health, Department of Non-Communicable Disease Epidemiology, Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Audrey Bonaventure
    Epidemiology of Childhood and Adolescent Cancers Team, CRESS, Université de Paris-INSERM, Villejuif, France.
  • Stephen P Pereira
    UCL Institute for Liver and Digestive Health, University College London, London, UK.
  • Laura M Woods
    Faculty of Epidemiology and Population Health, Department of Non-Communicable Disease Epidemiology, Inequalities in Cancer Outcomes Network, London School of Hygiene & Tropical Medicine, London, United Kingdom.

Keywords

External Resources

Popular Topics
Recent Journals